One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort ® Turbuhaler ®) for the treatment of asthma

Respiratory Medicine

Volumn 97, Issue 6, 2003, Pages 702-708

  Rosenhall, L ^a   Elvstrand, A ^d   Tilling, B ^d   Vinge, I ^d   Jemsby, P ^b   Stahl E ^c   Jerre, F ^c   Bergqvist, P B F ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b VARBERG HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d NONE

Author keywords

Asthma; Budesonide; Formoterol; Single inhaler

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CROMOGLYCATE DISODIUM; FORMOTEROL; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NEDOCROMIL SODIUM; XANTHINE DERIVATIVE;

ADULT; AGED; ARTICLE; ASTHMA; BACKACHE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; INTERMETHOD COMPARISON; LABORATORY TEST; LONG TERM CARE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PATIENT COMPLIANCE; PHARYNGITIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINITIS; SCORING SYSTEM; SINUSITIS; TREMOR; VIRUS INFECTION;

EID: 0037636766     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2003.1504     Document Type: Article

References (21)

1. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219-224.
2. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-1488.
3. Pauwels RC, Löfdahl C-G, Postma DS. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
4. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164(8 Pt 1): 1392-1397.
5. National Heart, Lung and Blood Institute, National Institutes of Health, World Health Organization. Global Initiative for Asthma. Pocket guide for asthma management. Bethesda: NIH/NHLBI, Publication No. 96-3659B, 1998.
6. Seberova E, Andersson A. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med 2000; 94: 607-611.
7. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Locvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10: 2484-2489.
8. Andersson F, Ståhl E, Barnes PJ, et al, for the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Adding formoterol to budesonide in moderate asthma - health economic results from the FACET study. Respir Med 2001; 95: 505-512.
9. Juniper EF, Svensson K, O'Byrne PM, et al. for the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J 1999; 14: 1038-1043.
10. Zetterström O, Buhl R, Mellem H. Improved asthma control with budesonide/formoterol in a single inhaler compared with budesonide alone. Eur Respir J 2001; 18: 262-268.
11. Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B, Thomson NC. Budesonide and formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroid in mild-moderate persistent asthma. Eur Respir J 2001; 18 (suppl 33): 159s.
12. Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B, Thomson NC. Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma. Eur Respir J 2001; 18 (suppl 33): 43s.
13. Rosenhall L, Heinig JH, Lindqvist A, Leegaard J, Stahl E, Bergqvist PBF. Budesonide/formoterol (Symbicort®) is well tolerated and effective in patients with moderate persistent asthma. Int J Clin Pract 56: 427-433.
14. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902-907.
15. Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999; 14: 32-38.
16. Cochrane GM. Compliance with prescribed therapy: how it is assessed and some factors that influence patient behaviour. Asthma J 1999; 4: 165-170.
17. Coutts JA, Gibson NA, Paton JY. Measuring compliance with inhaled medication in asthma. Arch Dis Child 1992; 3: 332-333.
18. Rosenhall L, Borg S, Andersson F, Ericsson K. Cost savings of long-term asthma treatment with budesonide/formoterol in a single inhaler compared with separate inhalers. Chest 2001; 120: 226s.
19. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158: 924-930.
20. Wallin A, Sandström T, Soderberg M. The effects of regular inhaled formoterol, budesonide and placebo on mucosal inflammation and clinical indices of mild asthma. Am J Respir Crit Care Med 1998; 158: 79-86.
21. Kips JC, O'Connor BJ, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the anti-inflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161: 996-1001.